Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Injectable Facility (F-III) located at Karakhadi. The report was received on 13th May 2026, following an inspection conducted by the USFDA from 9th February to 18th February 2026.
The receipt of the EIR signifies that the USFDA has completed its evaluation of the facility, which is a critical step in ensuring compliance with regulatory standards. The inspection process is a routine procedure aimed at assessing the manufacturing practices and ensuring that they meet the necessary quality and safety standards required for pharmaceutical production.
Alembic Pharmaceuticals had previously informed the exchange about the USFDA inspection at its Karakhadi facility in an earlier intimation dated 18th February 2026. The company has now officially communicated the receipt of the EIR to the National Stock Exchange of India (NSE) and BSE Limited.
This development is a significant milestone for Alembic Pharmaceuticals as it reflects the company’s adherence to stringent regulatory requirements and its commitment to maintaining high standards in its manufacturing processes.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).